Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
OncoSil Medical Ltd ( (AU:OSL) ) just unveiled an announcement.
OncoSil Medical Limited announced significant achievements in FY25, including regulatory progress and commercial expansion. The approval from Germany’s G-BA for a fully funded clinical trial is expected to enhance access to the OncoSil™ device in the German public hospital system, potentially influencing reimbursement negotiations across Europe. Additionally, the company achieved MDR certification, streamlining treatment initiation in the EU and UK, and recorded its first commercial sale in Germany. Clinical trials like PANCOSIL and TRIPP-FFX are nearing completion, with promising results supporting the efficacy of the OncoSil™ device.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a medical device company specializing in localized treatments for patients with unresectable locally advanced pancreatic cancer. The company focuses on expanding access to targeted radiation options for pancreatic cancer, aiming to improve survival rates in this challenging oncology area.
Average Trading Volume: 23,108
Technical Sentiment Signal: Sell
Current Market Cap: A$23.44M
For detailed information about OSL stock, go to TipRanks’ Stock Analysis page.